Dr. Mehran Farid-Moayer, MD

Dr. Farid-Moayer practices at Mid Peninsula Endoscopy Center in Burlingame, California.

Dr. Farid-Moayer's NPI, 1184690984, was assigned on February 23, 2006. Dr. Farid-Moayer graduated from Tehran University of Medical Sciences School of Medicine in 1991. Dr. Farid-Moayer holds California license A66203.

Dr. Farid-Moayer's primary practice is Mid Peninsula Endoscopy Center, at 1720 El Camino Real, Suite 100, Burlingame, CA 94010. The practice phone is (650) 373-1970.

Dr. Farid-Moayer's primary practice is Mid Peninsula Endoscopy Center in Burlingame, California. Dr. Farid-Moayer is also affiliated with Mills-Peninsula Medical Center. The medical group on file is Pulmonary Associates. Dmand AI also links Dr. Farid-Moayer to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Farid-Moayer practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Farid-Moayer's primary specialty in the NPI Registry, under taxonomy code 207RS0012X. The record also lists sleep medicine. Dr. Farid-Moayer is board certified in critical care medicine by the American Board of Internal Medicine. Dr. Farid-Moayer is licensed in California.

CMS data shows 692 Medicare services from Dr. Farid-Moayer across 10 procedure codes in 2024, for 467 Medicare patients. Medicare paid $86,564 for them.

CMS counts 467 Medicare patients who saw Dr. Farid-Moayer in 2024. The largest group is 65 to 74, with 231 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.14, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Farid-Moayer's median patient age at 57, with 39% women.

In 2024, Dr. Farid-Moayer wrote 303 Medicare Part D claims for 54 patients. 81% of them were for generic drugs. CMS names the drug for 258 of them, across 11 drugs with 11 or more claims each, at $44,433 in total drug cost. In 2023, CMS named 232 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Farid-Moayer for performance year 2024, reported as part of a group. Dr. Farid-Moayer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Farid-Moayer as offering telehealth.

Dmand AI links 6 papers to Dr. Farid-Moayer, published from 2012 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Polysomnography, Sleep Apnea, Obstructive and Palate, Soft. Dr. Farid-Moayer has published most often in Sleep Med. Dr. Farid-Moayer's most frequent co-authors are Jed Eric Black, MD, Lawrence Charles Siegel, MD and Philip Michael Becker, MD.

Dmand AI links Dr. Farid-Moayer to 4 clinical trials, 2 of them phase 4 studies. Conditions studied include Disorders of Excessive Somnolence, Sleep Disorders, Intrinsic and Cheyne-Stokes Respiration. Cephalon sponsors the most, 2.

CMS Open Payments shows 238 general payments to Dr. Farid-Moayer from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. GlaxoSmithKline, LLC. paid the most, $1,168.

Dmand AI lists 2 awards for Dr. Farid-Moayer, most recently CMS Stage 1 EHR in 2013.

Dr. Farid-Moayer graduated from Tehran University of Medical Sciences School of Medicine in 1991. Dr. Farid-Moayer is a member of AMA.

Dr. Farid-Moayer is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.